Open-label Extension Study in Participants With Early Alzheimer's Disease

To be considered for this study, you must have already completed the treatment part of the previous study (called 219867 or NCT06079190). It's okay if you missed a few doses or had a temporary break from the medication in the past, but you cannot have permanently stopped the study medication or left the previous study early.

You also need to be willing and able to understand and sign a consent form, which explains everything about the study. A trusted adult who knows you well and sees you often (like a family member or close friend) also needs to be available to provide information about your memory and daily activities, and they will need to sign a consent form too.

There are also some health conditions or medications that might mean you can't join. For example, if you have certain heart rhythm issues, specific brain conditions identified on an MRI scan, or new serious infections, you would likely not be able to take part. Women who are pregnant, breastfeeding, or of childbearing potential and not using specific contraception also can't participate. Both men and women need to follow contraception rules during the study. Participants should be between 50 and 85 years old.

If you decide to take part, you will continue to receive the study medication, GSK4527226. You will have regular visits to the clinic where the study doctors and nurses will monitor your health, memory, and thinking. These visits will help them understand how the medication is affecting you. They will also do tests and scans, which might include MRI scans, to check for any changes. Your study partner will also need to attend these visits to provide important information about your daily life and abilities. The total length of your participation will be discussed with you in detail, but it involves continued treatment and regular check-ups to assess the long-term effects of the medication.